INCY vs TECH — Key Metrics

Metric INCY (INCYTE CORP) TECH (BIO-TECHNE CORP)
Price117.872.75
Market Cap24.01 Billion11.43 Billion
P/E (TTM)56.3666.14
P/B (Quarterly)4.2195.284
P/S (TTM)3.999.3
Net Profit Margin (TTM)6.714.0
Gross Margin (TTM)92.765.8
ROE (TTM)7.18.2
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

INCYTE CORP
vs
 
BIO-TECHNE CORP
 
INCYTE CORP
vs
 
BIO-TECHNE CORP
Performance Comparison
AI Model Recommendation
INCY · INCYTE CORP

Greatly Outperform

84
UnderperformOutperform
TECH · BIO-TECHNE CORP

Underperform

-43
UnderperformOutperform
Recommendation Summary

Stock INCY is projected to greatly outperform the market, stock TECH is projected to underperform the market. Upfront Recommendation: INCY.

Financial Metrics
Prices delayed ~15 min
INCY Metrics TECH
$117.80 Price $72.75
— Market Capitalization —
56.36 Price to Earnings Ratio 66.14
3.99 Price to Sales 9.3
35.06 Price to FCF Ratio 37.08
4.31 Price to Gross Profit 14.15
6.99 Price to R&D 117.98
4.35 Price to Current Assets 13.86

INCY vs TECH at a glance

Incyte Corp (INCY) and Bio-techne Corp (TECH) are both Biotechnology companies in the Healthcare sector. INCY is the larger, at $24.0 billion in market value against $11.4 billion for TECH, about 2.1 times the size.

On trailing-twelve-month figures, INCY trades at 56.4 times trailing earnings and TECH at 66.1; net profit margins are 6.7% and 14.0%.

The Upfront Investment model currently rates INCY Greatly Outperform and TECH Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.